Patient and healthcare professional experiences of the Salford Lung Studies: qualitative insights for future effectivene
- PDF / 1,665,465 Bytes
- 12 Pages / 595.276 x 790.866 pts Page_size
- 51 Downloads / 143 Views
RESEARCH
Open Access
Patient and healthcare professional experiences of the Salford Lung Studies: qualitative insights for future effectiveness trials Kim Gemzoe1* , Rebecca Crawford2, Ann Caress3, Sheila McCorkindale4, Rebecca Conroy2, Susan Collier5, Lynda Doward2, Renu M. Vekaria2, Sally Worsley6, David A. Leather7 and Elaine Irving6
Abstract Background: Randomized controlled trials (RCTs) conducted in the routine care setting provide the opportunity to better understand the effectiveness of new medicines but can present recruitment difficulties. An improved understanding of the challenges/opportunities for patient and healthcare professional (HCP) engagement in clinical research is needed to enhance participation and trial experience. In this study, we explored patient and HCP drivers for, and experiences of, participation in the Salford Lung Studies (SLS), and their views on future trial participation and the overall value of such trials. Methods: This was a qualitative study set in Salford, UK, comprising patient telephone interviews (N = 10) and HCP advisory boards (one with general practitioners [GPs], one with practice managers [PMs]); all individuals had participated in the SLS. Semi-structured telephone interviews were recorded, transcribed and analysed thematically. Advisory board meetings were analysed based on transcriptions of audio recordings and field notes. Results: For patients, key positive aspects of the SLS were the ease/convenience of study assessments and excellent relationships with study nurses. GPs and PMs considered the SLS to be well-organized and highlighted the value of research nurse support; they also described minor challenges relating to trial systems, initial financial strain on practices and staff turnover. All participants indicated that they were very likely to participate in future trials, citing a design closely aligned with routine care practice as essential. Several strategies to encourage trial participation were suggested, such as clearly communicating benefits to patients and ensuring flexible study assessments. (Continued on next page)
* Correspondence: [email protected] The affiliation "RTI Health Solutions, Manchester M20 2LS, UK" was Dr. Rebecca Conroy's affiliation at the time of the study and during manuscript preparation. 1 Real World Study Delivery, Value Evidence and Outcomes, GlaxoSmithKline plc., Research & Development Ltd., Stockley Park West, 1–3 Ironbridge Road, Uxbridge, Middlesex UB11 1BT, UK Full list of author information is available at the end of the article © The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence,
Data Loading...
